[1] |
张学军, 郑捷. 皮肤性病学[M]. 9版. 北京: 人民卫生出版社, 2018:133.
|
[2] |
Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study[J]. BMJ, 2020,369:m1590.
|
[3] |
华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2023版)[J]. 中华皮肤科杂志, 2023, 56(7):573-625.
|
[4] |
Torales J, Echeverría C, Barrios I, et al. Psychodermatological mechanisms of psoriasis[J]. Dermatol Ther, 2020, 33(6):e13827.
|
[5] |
Novartis Pharma Schweiz AG. 司库奇尤单抗注射液说明书(2022年版)[EB/OL]. 2022. https://www.novartis.com.cn/products/pharmaceuticals.
|
[6] |
Papp KA, Gooderham M, Lynde C, et al. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry[J]. Arch Dermatol Res, 2024, 316(7):362.
|
[7] |
Shi X, Jin L, Dang E, et al. IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms[J]. J Invest Dermatol, 2011, 131(12):2401-2408.
doi: 10.1038/jid.2011.222
pmid: 21796151
|
[8] |
Jin L, Wang G. Keratin 17: a critical player in the pathogenesis of psoriasis[J]. Med Res Rev, 2014, 34(2):438-454.
doi: 10.1002/med.21291
pmid: 23722817
|
[9] |
Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis[J]. Chin Med J (Engl), 2020, 133(22):2665-2673.
|
[10] |
Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies[J]. Drug Discov Today, 2006 11(1-2):81-88.
doi: 10.1016/S1359-6446(05)03638-X
pmid: 16478695
|
[11] |
Karataş A, Gerçek AN, Öz B, et al. The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis[J]. Eur J Rheumatol, 2020, 7(4):169-172.
|
[12] |
Ikuma D, Oguro M, Hoshino J, et al. Efficacy of secukinumab for plaque psoriasis in a patient on hemodialysis[J]. CEN Case Rep, 2020, 9(1):55-58.
|
[13] |
Mukai M, Kurihara Y, Ito Y, et al. Successful treatment with secukinumab of three psoriatic patients undergoing dialysis[J]. J Dermatol, 2020, 47(1):e26-e28.
doi: 10.1111/1346-8138.15132
|
[14] |
Pizzatti L, Mugheddu C, Sanna S, et al. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab[J]. Dermatol Ther, 2020, 33(3):e13348.
|
[15] |
Cao Z, Liu Z, Zhu X, et al. Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis[J]. Ren Fail, 2022, 44(1):826-830.
doi: 10.1080/0886022X.2022.2073893
pmid: 35546261
|